Tuberculosis Treatment Completion Among Persons Incarcerated at Diagnosis, U.S. TB Surveillance System, 1999–2008 Kiren Mitruka, MD, MPH (presented on.

Slides:



Advertisements
Similar presentations
Allison Dunning, M.S. Research Biostatistician
Advertisements

Figure 1. Number of Tuberculosis Cases: California, California Department of Public Health, Tuberculosis Control Branch Number of Tuberculosis.
Endemic or Outbreak? Differentiating recent transmission of an historic tuberculosis strain in New York City IUATLD-NAR 16 th Annual Meeting February 23-25,
Mortality Among a Tuberculosis Outbreak Los Angeles County, 2007–2013 Brian Baker, MD Amit Chitnis, MD MPH Leslie Henry, BSN RN PHN 48th CTCA Educational.
B WAIVERS: A YEAR IN REVIEW MARCH 20, 2014 MARYLAND DEPARTMENT OF HEALTH AND MENTAL HYGIENE PREVENTION AND HEALTH PROMOTION ADMINISTRATION ANDREA E. PALMER,
Mortality and causes of death among women living with HIV in the UK in the era of highly-active antiretroviral therapy Sara Croxford, A Kitching, M Kall,
National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention Division of HIV/AIDS Prevention Epidemiology of HIV Infection through 2012.
Unintentional Fall Injuries and Deaths Among MA Older Adults, Ages 65 Years and Over Carrie Huisingh, MPH, Epidemiologist Holly Hackman, MD, MPH, Epidemiologist.
World Tuberculosis Day 2015 The TB situation in 2013: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.
HIV/AIDS Prevalence & Mortality Report, 2010 Minnesota Department of Health HIV/AIDS Surveillance System Minnesota Department of Health HIV/AIDS Surveillance.
HIV Surveillance – Persons Who Inject Drugs National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention Division of HIV/AIDS Prevention.
HIV Surveillance by Race/Ethnicity National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention Division of HIV/AIDS Prevention.
World Tuberculosis Day 2014 The TB situation in 2012: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.
Tuberculosis in the UK 2013 report
Tuberculosis in the UK 2014 report
The Global Plan to Stop TB, (1)
Culture Conversion and Self- Administered Therapy in Privately Managed Tuberculosis Patients Melissa Ehman MPH, Jennifer Flood MD MPH, Pennan Barry MD.
Figure 1. Number of Tuberculosis Cases: California, California Department of Public Health, Tuberculosis Control Branch Number of Tuberculosis.
Surveillance to measure impact of ART Theresa Diaz, MD MPH CDC Global AIDS Program.
Assessment of Program Evaluation Activities in Tuberculosis Control Programs — United States, 2009–2010 Silvia M. Trigoso, MPH Fellow, Public Health Prevention.
Global and U.S. Tuberculosis Epidemiology and Principles of Control
Use of Network Analysis During a Tuberculosis Investigation Outbreak Investigation Section Surveillance and Epidemiology Branch Division of Tuberculosis.
The Changing Landscape of TB: Maryland TB in 2013 Presented by Dr. David Blythe Lisa Paulos, RN MPH, Epidemiologist Center for TB Control & Prevention.
Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.
1 Epidemiology of Pediatric Tuberculosis in the United States, 1993–2006 Surveillance, Epidemiology, and Outbreak Investigations Branch Division of Tuberculosis.
Division of Tuberculosis Elimination Centers for Disease Control and Prevention Tuberculosis in the United States National Surveillance System Highlights.
Comparison of Molecular and Conventional Methods for Detection of Multidrug-Resistant Tuberculosis in the United States, 2009 to 2011 Mitchell A. Yakrus,
Colorado Department of Public Health and Environment Tuberculosis Prevention and Control Program.
Determination of HIV Infection Among TB Patients in California, 2008 Darryl Kong 1, Jennifer Flood 1, Suzanne Marks 2, James Watt 1 1 California Department.
Using HIV Surveillance to Achieve High Impact Prevention Irene Hall, PhD, FACE AIDS 2012 High-Impact Prevention: Reducing the HIV Epidemic in the United.
Theodore M. Hammett, Ph.D. Sofia Kennedy, M.P.H. Drug Abuse and Risky Behaviors: The Evolving Dynamics of HIV/AIDS NIH-Bethesda, MD May 9, 2007 HIV/AIDS.
Division of Tuberculosis Elimination Centers for Disease Control and Prevention Tuberculosis in the United States National Tuberculosis Surveillance System.
Tuberculosis in the United States National Tuberculosis Surveillance System Highlights from 2011 National Center for HIV/AIDS, Viral Hepatitis, STD, and.
Sanghyuk Shin, PhD Department of Epidemiology UCLA Fielding School of Public Health Aug 27, 2015 Tuberculosis and HIV Co-infection: “A Deadly Syndemic”
2,500 3,000 3,500 4,000 4,500 5,000 5,500 6,000 2,500 3,000 3,500 4,000 4,500 5,000 5,500 6,000 Figure 1. Number of Tuberculosis Cases: California,
Surveillance Data in Action: Tuberculosis Indicators Melissa Ehman, MPH Tuberculosis Control Branch (TBCB) Division of Communicable Disease Control Center.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
Monitoring Indicators of the National HIV/AIDS Strategy Using Data for Public Health Action Irene Hall, PhD, FACE HIV Incidence and Case Surveillance Branch.
Introduction to NCHHSTP National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Office of the Director Jonathan Mermin, MD, MPH National.
Epidemiology of Tuberculosis in African-American Population, United States Kenneth G. Castro, M.D. Assistant Surgeon General, USPHS Director,
Epidemiology of Tuberculosis in Correctional Facilities, United States, Surveillance, Epidemiology and Outbreak Investigations Branch Division.
Number of Tuberculosis Cases: California, Number of Tuberculosis Cases.
Surveillance, Epidemiology, and Outbreak Investigations Branch Division of Tuberculosis Elimination Centers for Disease Control and Prevention (CDC) Epidemiology.
California Update : TB Epidemiology and Indicators CTCA October 22, 2010 Jennifer Flood MD MPH Chief, Surveillance and Epidemiology Tuberculosis Control.
HIV Surveillance in Urban and Nonurban Areas through 2013 National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention Division of HIV/AIDS Prevention.
Surveillance, Epidemiology, and Outbreak Investigations Branch Division of Tuberculosis Elimination Centers for Disease Control and Prevention (CDC) Epidemiology.
HIV Surveillance by Race/Ethnicity
TB Prevention and Control in Correctional and Detention Facilities Mark Lobato, MD Division of TB Elimination Centers for Disease Control and Prevention.
Predictors of Failure in Timely TB Treatment Completion, United States Carla Winston,PhD TB PEN Focal Point Open Forum June 5,
Figure 1. Number of Tuberculosis Cases: California, Number of Tuberculosis Cases
Trends in HIV Infection, Stage 3 (AIDS) National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention Division of HIV/AIDS Prevention.
HIV Surveillance in Women National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention Division of HIV/AIDS Prevention.
A Survival Comparison between HIV+ U.S.-born Latinos and Foreign-born Latinos in Houston, Texas Raouf Arafat, MD, MPH, Adebowale Awosika- Olumo.
T T H H I I Tennessee Health Indicators PROGRAM DIRECTOR: DR. JON WARKENTIN DATA DIRECTOR/EPIDEMIOLOGIST: JASON CUMMINS, MPH Tuberculosis Elimination Program.
TB Control Program County of San Diego County of San Diego Health and Human Services Agency Tuberculosis Control Branch Trends in Tuberculosis Highlights.
Tuberculosis in the United States
Tuberculosis in the United States
Tuberculosis in the United States
World Tuberculosis Day 2014
World Tuberculosis Day 2013
World Tuberculosis Day 2014
Tuberculosis in the United States
World Tuberculosis Day 2015
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
World Tuberculosis Day 2014
World Tuberculosis Day 2016
World Tuberculosis Day 2014
Hepatitis B Vaccination Assessment Adults Aged Years National Health Interview Survey, 2000 Gary L. Euler, DrPH1, Hussain Yusuf, MBBS2, Shannon.
Tuberculosis in Wales Annual Report 2018 Data to the end of 2017
Tuberculosis in Wales Annual Report 2017 Data to the end of 2016
Presentation transcript:

Tuberculosis Treatment Completion Among Persons Incarcerated at Diagnosis, U.S. TB Surveillance System, 1999–2008 Kiren Mitruka, MD, MPH (presented on her behalf by Maryam Haddad) Surveillance, Epidemiology, and Outbreak Investigations Branch ACET Meeting — March 7, 2012 National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of TB Elimination

Background: Treatment Completion  Treatment completion is a top priority for TB control  Interrupted or incomplete treatment increases risk of relapse, transmission, and drug resistance  Most forms of TB are treatable within 6 – 9 months  2015 national target: 93% completion (COT) within 12 months among persons eligible for COT ≤12 months

Background: National TB Surveillance  National TB Surveillance System (NTSS) began to collect reason therapy stopped (treatment outcome) in 1993  Also in 1993, NTSS began recording whether patient residing in correctional facility at time of TB diagnosis  Federal prison, state prison, local jail, juvenile facility, other  In 2009, additional variable to ascertain whether under custody of Immigration and Customs Enforcement (ICE)

Overall Treatment Completion  Overall proportion of cases ever completing treatment 87%  92% during 1993–2008  Among persons alive at diagnosis, with initial regimens of at least one TB drug, who did not die during treatment  Treatment completion within 12 months: 63%  85%  Improved but falls short of national goal of 93%  Excluded from expectation/calculation of COT≤12 months if Not on at least one TB drug, death at diagnosis or during treatment, meningeal disease, pediatric miliary disease or TB bacteremia, or rifampin monoresistance or multidrug resistance (MDR) on initial drug susceptibility testing Source: Mitruka et al. Predictors of failure in timely tuberculosis treatment completion, United States. Accepted by IJTLD, Feb 2012.

Incarcerated Persons as a Proportion of All TB Cases, 1993–2010

Trends in TB Cases in Incarcerated Persons, 1993–2010

Treatment Completion Among Persons Incarcerated at Diagnosis  For 1999–2008 cohort, examined treatment outcomes among incarcerated vs. not incarcerated  Among all persons alive at diagnosis who started treatment, reason therapy stopped  Among persons eligible for completion (COT) in ≤12 months, stratified by origin (i.e., U.S.-born and foreign-born): – completion in ≤12 months – delayed completion (>12 months) – no known completion o by facility at diagnosis

Reason TB Treatment Stopped, 1999–2008, by Incarceration Status (N=143,515) Incarcerated at diagnosis N=4,986 n (%) Not incarcerated N=138,390 n (%) Completed treatment ever 3,641(73.0)119,505(86.4) Died173(3.5)10,282(7.4) Moved364(7.3)3,036(2.2) Lost571(11.5)3,078(2.2) Refused44(0.9)844(0.6) Adverse event0(0.0)5 Unknown, other, or missing 193(3.9)1,640(1.2) Note: Included all cases in persons reported as alive at diagnosis and taking one or more TB drugs; 139 cases (0.1% ) had missing incarceration status

Reason TB Treatment Stopped, 1999–2008, Among Incarcerated, by Origin (N= 4,986) U.S.-born N=3,148 n (%) Foreign-born N=1,814 n (%) Completed treatment 2,569(81.6)1,057(58.3) Died142(4.5)31(1.7) Moved90(2.9)271(14.9) Lost256(8.1)312(17.2) Refused25(1.0)19(1.1) Adverse event0(0.0)0 Unknown, other, or missing 66(2.1)124(6.8) Note: Of total 4,986 cases among incarcerated persons, 24 had missing data on origin

Treatment Completion in ≤12 Months by Incarceration Status at Diagnosis* * Cases were among persons eligible to complete treatment within 12 months: persons had to be alive at diagnosis, initiate TB treatment, not die during treatment, and not have meningeal TB, pediatric (aged <15 years) miliary disease or a positive blood culture for Mycobacterium tuberculosis, or rifampin resistance on initial drug susceptibility testing

Treatment Completion in >12 Months by Incarceration Status at Diagnosis* * Cases were among persons eligible to complete treatment within 12 months: persons had to be alive at diagnosis, initiate TB treatment, not die during treatment, and not have meningeal TB, pediatric (aged <15 years) miliary disease or a positive blood culture for Mycobacterium tuberculosis, or rifampin resistance on initial drug susceptibility testing

No Known Treatment Completion by Incarceration Status at Diagnosis* *Cases were among persons eligible to complete treatment within 12 months: persons had to be alive at diagnosis, initiate TB treatment, not die during treatment, and not have meningeal TB, pediatric (aged <15 years) miliary disease or a positive blood culture for Mycobacterium tuberculosis, or rifampin resistance on initial drug susceptibility testing

Treatment Completion in ≤12 Months Among Incarcerated, by Origin* *Cases were among persons eligible to complete treatment within 12 months: persons had to be alive at diagnosis, initiate TB treatment, not die during treatment, and not have meningeal TB, pediatric (aged <15 years) miliary disease or a positive blood culture for Mycobacterium tuberculosis, or rifampin resistance on initial drug susceptibility testing

Treatment Completion in >12 Months Among Incarcerated, by Origin * *Cases were among persons eligible to complete treatment within 12 months: persons had to be alive at diagnosis, initiate TB treatment, not die during treatment, and not have meningeal TB, pediatric (aged <15 years) miliary disease or a positive blood culture for Mycobacterium tuberculosis, or rifampin resistance on initial drug susceptibility testing

No Known Treatment Completion Among Incarcerated, by Origin * *Cases were among persons eligible to complete treatment within 12 months: persons had to be alive at diagnosis, initiate TB treatment, not die during treatment, and not have meningeal TB, pediatric (aged <15 years) miliary disease or a positive blood culture for Mycobacterium tuberculosis, or rifampin resistance on initial drug susceptibility testing

No Known Treatment Completion by Facility Type at Diagnosis and Origin, 1999–2008 U.S.-bornForeign-born n(%) No known completion n Total incarcerated2,965(14.6)1,753(40.6) Federal prison112(21.4)314(54.5) State prison1,003(10.8)130(30.8) Local jail1,680(16.2)791(32.1) Juvenile corrections 26(3.9)16(18.8) Other*78(14.1)483(49.3) Unk/missing66(27.4)19(0.4) *Other= ICE detention center, Indian reservation facilities, military stockades and jails, federal park police facilities, police lockups temporary holding facilities), and other facilities not included in other specific choices

Conclusions  Persons incarcerated at diagnosis are at high risk for not having timely treatment completion  Trends in timely completion worsening  Failure is largely attributed to no known completion rather than delayed completion  Foreign-born at particularly high risk for having no documented completion

Acknowledgment  Author of presentation, Kiren Mitruka  Data analysis (ongoing), development of presentation  Currently on an Epi-Aid for a TB outbreak  Steve Kammerer and Bob Pratt  Technical support